Login
Enter your Progress In Mind Portugal username.
Enter the password that accompanies your username.

Request new password

Home

Progress in Mind Portugal

  • Topics
    • Depression
    • Migraine
    • Schizophrenia
  • Congress highlights
    • EAN 2022
    • AAN 2022
    • AHS 2022
    • AAN 2021
    • AHS 2021
    • IHC 2021
    • SIRS 2019
    • EPA 2019
    • EPA 2018
    • APA 2018
    • ECNP 2017
  • About
  • Podcasts
  • Newsletter signup

Search

Main navigation

  • Home
  • Lundbeck Therapeutic Area Australia
  • Progress in Mind Korea Focus Area
  • Progress in Mind Spain Focus Area
  • 전문가 칼럼
  • 찾아보기

Tools

  • 찾아보기
  • User Profile

User account menu

  • Log in
  • Reset your password
Powered by Drupal

The information on this site is exclusively intented for health care professionals.

Accept Decline
Depression 12 May, 2023 Read Time: 1 min

Que experiência têm os profissionais de saúde com a utilização da dose de 20 mg de Brintellix® para tratar os seus doentes com TDM?

Saiba mais sobre a experiência do Professor Andrea Fagiolini com a dose de 20 mg no webinar que se segue.

Sign up for Progress in Mind Portugal newsletter

Sign up for our newsletter and stay updated on new content and resources.

Related

Migraine
Congress highlights

If at first you don’t succeed, try another CGRP antibody for migraine prevention?

Migraine
Congress highlights

New insights from a poster at IHC2021 on the depiction of migraine in the media

Migraine
Satellite symposium Article

Getting a head start on Migraine Prevention

Social Networks

Progress in Mind Portugal HCP Access verification required

To gain access, please provide details to verify you are a healthcare professional.

If you are not located in Portugal click here.

Continue to verification page Login with email

Brought to you by

 Lundbeck

© 2021

PROGRESS IN MIND PORTUGAL

Cookies

Condições de Utilização

subscribe newsletter

Sign up for newsletter

Register as a health care professional

Login as a registered health care professional

Please enter your email to continue

By submitting this form you agree that your email is sent to a third party for validation.

Read the full terms and conditions here.